CAM
GRCL

Cormorant Asset Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Cormorant Asset Management’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-125,000
Closed -$1.93M – 127
2021
Q1 		$1.93M Buy
+125,000
New +$2.95M 0.04% 109

Other funds holding GRCL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
CloudAlpha Capital Management Hong Kong $2.93B AUM 345.92% 1-Year Est. Return

Cormorant Asset Management's GRCL Position: Q2 2021 in Review

Cormorant Asset Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q2 2021, closing a stake of 125,000 shares — an estimated $1.93M sold.

Cormorant Asset Management first reported a position in GRCL in Q1 2021 and held it in 1 quarter. The position peaked at $1.93M in Q1 2021. 32 funds tracked by Wall St. Rank hold GRCL as of Q2 2021.

  • Cormorant Asset Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q2 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 125,000 Gracell Biotechnologies Inc. American Depositary Shares shares in Q2 2021, an estimated $1.93M.
  • Cormorant Asset Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 1 quarter.
  • Cormorant Asset Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $1.93M in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.